MHRA grants conditional approval for Wegovy to treat MASH with fibrosis; NHS access awaits NICE review
MHRA conditionally approves Novo Nordisk’s Wegovy (semaglutide) for MASH with fibrosis; NHS availability depends on NICE appraisal and further trial data.